ACRIX
Price
$27.69
Change
+$0.12 (+0.44%)
Updated
Jun 12 closing price
Net Assets
1.57B
FLDFX
Price
$14.56
Change
+$0.05 (+0.34%)
Updated
Jun 12 closing price
Net Assets
487.47M
Interact to see
Advertisement

ACRIX vs FLDFX

Header iconACRIX vs FLDFX Comparison
Open Charts ACRIX vs FLDFXBanner chart's image
ACRIX vs FLDFX Comparison Chart in %
View a ticker or compare two or three
VS
ACRIX vs. FLDFX commentary
Jun 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACRIX is a Buy and FLDFX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
ACRIX has more cash in the bank: 1.57B vs. FLDFX (487M). FLDFX pays higher dividends than ACRIX: FLDFX (0.85) vs ACRIX (0.67). ACRIX was incepted earlier than FLDFX: ACRIX (10 years) vs FLDFX (20 years). FLDFX (1.47) is less costly to investors than ACRIX (1.15). FLDFX is a more actively managed with annual turnover of: 243.00 vs. ACRIX (172.00). FLDFX has a lower initial minimum investment than ACRIX: FLDFX (2500) vs ACRIX (10000000). FLDFX annual gain was more profitable for investors over the last year : 15.48 vs. ACRIX (12.48). FLDFX (11.97) and ACRIX (11.82) have equivalent 5 years return.
ACRIXFLDFXACRIX / FLDFX
Total Expense Ratio1.151.4778%
Annual Report Gross Expense Ratio1.151.4778%
Fund Existence10 years20 years-
Gain YTD9.9257.699129%
Front LoadN/AN/A-
Min. Initial Investment100000002500400,000%
Min. Initial Investment IRAN/AN/A-
Net Assets1.57B487M322%
Annual Yield % from dividends0.670.8578%
Returns for 1 year12.4815.4881%
Returns for 3 years30.4625.66119%
Returns for 5 years11.8211.9799%
Returns for 10 yearsN/A57.87-
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MMA0.440.01
+1.75%
Mixed Martial Arts Group Limited
CHT46.090.09
+0.20%
CHUNGHWA TELECOM CO Ltd
BFH101.710.08
+0.08%
Bread Financial Holdings
TALK5.21N/A
N/A
Talkspace
ABOS2.37N/A
N/A
Acumen Pharmaceuticals